Ajanta Pharma plans to sell generic semaglutide in 26 countries, in a partnership with Biocon, capitalizing on patent expirations. With a strong foothold in emerging markets and a potential 10x market growth, Ajanta aims to become a leading player in the global GLP-1 market by 2027.